US sales - mixed bag: We expect US market to remain steady on QoQ basis with continued challenging environment, partly offset by seasonality. Sun Pharma's specialty sales to enhance in Q3FY22 on successful launch of WINLEVI product. On favorable flu season, Lupin is expected to grow QoQ. We believe Cadila's US sales to decline QoQ, due to increased competition from Asacol HD partly offset by strong flu season. Indoco US sales to see QoQ pick up aided by profit share from Brinzolamide. ARBP US sales to decline on...